GN-HEARING
GN Hearing, the global leader in hearing aid innovation, today unveils ReSound Key, a full essential hearing aid line-up that provides greater access to proven and award-winning hearing technology worldwide. Based on an advanced chip platform and GN’s Organic Hearing philosophy, ReSound Key promises clear, natural sound quality. It is also packed with the latest technology, such as rechargeable options and state-of-the-art streaming, so that more people can now stay connected to live life to the fullest.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210201005069/en/
Today, only one in five of those who could benefit from hearing aids are using themi , leaving a large proportion to miss out on life’s sounds, communicating with family, and socializing with friends. The long-awaited ReSound Key is set to make a huge difference to people with all types of hearing loss. People can boost their confidence and connect with others and the world during times of social isolation; all with clear sound and leading rechargeability that offers up to 30 hours of power from one charge. They can enjoy direct streaming using iOS and Android™ devices and state-of-the-art Bluetooth® Low Energy.
Not treating hearing loss comes at a personal cost, with implications for physical, social, emotional, and mental health.ii,iii,iv However, professional guidance is at hand, even remotely, thanks to the innovative telehealth solution, ReSound Assist Live. With this agile at-home service, hearing care professionals can program and adjust ReSound Key hearing aids via video consultations to help people grow with their hearing and nurture their relationships.
GN Hearing CEO and President, Gitte Aabo, explains: “At GN Hearing, we believe that everyone deserves great hearing. Treating hearing loss can radically transform lives, helping people to thrive and grow. The launch of ReSound Key gives more people access to the best care and professional guidance, which helps them feel more confident and stay in touch with others to participate fully in life.”
ReSound Key joins the groundbreaking ReSound ONETM with M&RIE* and ReSound LiNX Quattro™ in the strongest and broadest ReSound portfolio yet, which offers premium hearing solutions at all price levels. Now more people can benefit from the company’s long-standing Organic Hearing philosophy to connect with the world around them in the most intuitive and natural way, which is inspired by how the ear works and the natural ways we listen.
Working with intuitive apps, ReSound Key further enhances the individualized hearing experience and can connect to a range of wireless accessories for additional help in challenging listening situations. New integrated, streamlined fitting and software updates ensure a seamless first fit and customer satisfaction. These updates make it easier than ever to offer the ReSound portfolio for users to enjoy.
ReSound Key is available in 10 models, including the popular rechargeable Receiver-in-Ear (RIE) design, custom hearing aids, and Behind-the-Ear (BTE) options – even including high power and super power models for profound hearing loss. ReSound Key will roll out in markets around the world from February 1, 2021. The same technology and models are also available in the new Beltone Rely hearing aid portfolio.
For further information, visit the ReSound Newsroom and learn about the Organic Hearing philosophy. A ReSound Virtual Conference is hosted for hearing care professionals in the United States on February 2, 2021.
– ENDS –
NOTES TO EDITORS
About ReSound
ReSound hearing aids, available from leading hearing care professionals, continue to set worldwide standards for quality and intuitive technology to help people with hearing loss communicate better than ever before. ReSound was the first hearing aid brand to be Made for iPhone, bringing direct streaming from hearing aids into the iPhone era. It also pioneered the development of 2.4 GHz wireless technology and made it possible to receive advanced at-home hearing care during COVID-19. The recent introduction of a new class of hearing technology with ReSound ONE demonstrates that ReSound is the undisputed innovation leader putting people with hearing loss at the center. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com, get to know our innovation and leadership , and connect with us on LinkedIn and Facebook .
*ReSound ONE introduced the world’s first full-featured hearing aid with M&RIE. Microphone and Receiver In Ear, for a truly individualized, more complete sound experience. ‘Full-featured’ means a microphone in the ear and two additional, standard directional microphones, directionality features and wireless audio streaming.
© 2021 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC. Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG, Inc
i World Health Organization (WHO) 2020: https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss
ii Hearing loss and incident dementia. Lin et al 2011
iii The impact of communication impairments on the social relationships of older adults: Pathways to psychological well-being. Palmer et al 2019
iv Hearing loss and associated medical conditions among individuals 65 years and older. McKee et al 2018
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005069/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom